Cover Image
市場調查報告書

包涵體肌炎 - 開發中產品分析

Inclusion Body Myositis (IBM) - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 271829
出版日期 內容資訊 英文 69 Pages
訂單完成後即時交付
價格
Back to Top
包涵體肌炎 - 開發中產品分析 Inclusion Body Myositis (IBM) - Pipeline Review, H2 2016
出版日期: 2016年10月29日 內容資訊: 英文 69 Pages
簡介

包涵體肌炎(IBM)是一種少見的慢性發炎性肌肉病變,肌肉、是由於供給肌肉血液的血管等相關組織發炎所引起。手指、手、大腿肌肉等肌肉力量漸漸低落。

本報告提供包涵體肌炎(IBM)的治療藥開發情形調查分析,提供您開發中產品的概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

目錄

簡介

包涵體肌炎(IBM)概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

開發中的治療藥:各企業

開發中產品的概要

  • 後期階段的產品
  • 臨床階段的產品

開發中的產品:各企業

治療藥的開發企業

  • Acceleron Pharma, Inc.
  • New Zealand Pharmaceuticals Limited
  • Nobelpharma Co., Ltd.
  • Novartis AG
  • Ultragenyx Pharmaceutical Inc.

治療藥的評估

  • 單獨療法的產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • AAV1-FS-344
  • ACE-083
  • aceneuramic acid
  • bimagrumab
  • DEXM-74
  • UX-007

最新的開發平台資訊

開發暫停中的計劃

產品開發的里程碑

  • 關註資訊和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8613IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Inclusion Body Myositis (IBM) - Pipeline Review, H2 2016, provides an overview of the Inclusion Body Myositis (IBM) (Musculoskeletal Disorders) pipeline landscape.

Inclusion Body Myositis (IBM) is one of the inflammatory myopathies that involve inflammation of the muscles or associated tissues, such as the blood vessels that supply the muscles. IBM symptoms include progressive weakness of the muscles of the wrists and fingers, the muscles of the front of the thigh, and the muscles that lift the front of the foot.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Inclusion Body Myositis (IBM) - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Inclusion Body Myositis (IBM) (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Inclusion Body Myositis (IBM) (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Inclusion Body Myositis (IBM) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 1, 2, 2, 2 and 2 respectively for Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively for Inclusion Body Myositis (IBM).

Inclusion Body Myositis (IBM) (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Inclusion Body Myositis (IBM) (Musculoskeletal Disorders).
  • The pipeline guide reviews pipeline therapeutics for Inclusion Body Myositis (IBM) (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Inclusion Body Myositis (IBM) (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Inclusion Body Myositis (IBM) (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Inclusion Body Myositis (IBM) (Musculoskeletal Disorders)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Inclusion Body Myositis (IBM) (Musculoskeletal Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Inclusion Body Myositis (IBM) (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Inclusion Body Myositis (IBM) Overview
  • Therapeutics Development
    • Pipeline Products for Inclusion Body Myositis (IBM) - Overview
    • Pipeline Products for Inclusion Body Myositis (IBM) - Comparative Analysis
  • Inclusion Body Myositis (IBM) - Therapeutics under Development by Companies
  • Inclusion Body Myositis (IBM) - Therapeutics under Investigation by Universities/Institutes
  • Inclusion Body Myositis (IBM) - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Inclusion Body Myositis (IBM) - Products under Development by Companies
  • Inclusion Body Myositis (IBM) - Products under Investigation by Universities/Institutes
  • Inclusion Body Myositis (IBM) - Companies Involved in Therapeutics Development
    • Acceleron Pharma, Inc.
    • Escala Therapeutics, Inc.
    • Milo Biotechnology LLC
    • Nobelpharma Co., Ltd.
    • Novartis AG
    • Orphazyme ApS
    • Ultragenyx Pharmaceutical Inc.
  • Inclusion Body Myositis (IBM) - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • AAV1-Follistatin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ACE-083 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • aceneuramic acid - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ALZ-801 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • arimoclomol - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • bimagrumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DEXM-74 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gene Therapy for Hereditary Inclusion Body Myopathy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • UX-001P - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • UX-007 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Inclusion Body Myositis (IBM) - Dormant Projects
  • Inclusion Body Myositis (IBM) - Product Development Milestones
    • Featured News & Press Releases
      • Jul 27, 2016: Ultragenyx Announces Completion of Enrollment in Phase 3 Study of Aceneuramic Acid Extended Release (Ace-ER) in GNE Myopathy
      • Apr 21, 2016: MorphoSys : MorphoSys Provides Update on Results From Partner Phase 2b/3 RESILIENT Study of Bimagrumab
      • Oct 02, 2015: Ultragenyx Announces Aceneuramic Acid Prolonged Release Marketing Authorization Application Filed and Accepted for Review by European Medicines Agency
      • May 28, 2015: Ultragenyx Announces First Patient Enrolled in Global Phase 3 Study of Aceneuramic Acid (Sialic Acid) Extended Release in GNE Myopathy
      • Jan 12, 2015: Ultragenyx Announces Intent to File for Conditional Approval in Europe for Sialic Acid Extended-Release Tablets in Hereditary Inclusion Body Myopathy
      • Oct 13, 2014: Ultragenyx Announces Interim Data From Phase 2 Extension Study of Sialic Acid Extended-Release at International Congress of the World Muscle Society
      • Apr 30, 2014: Ultragenyx Announces Positive Data From Phase 2 Study of Sialic Acid Extended-Release at Emerging Sciences Session of American Academy of Neurology Annual Meeting
      • Dec 20, 2013: Ultragenyx Announces Results from Phase 2 Study of Sialic Acid Extended-Release Treatment in Hereditary Inclusion Body Myopathy
      • Oct 02, 2013: MorphoSys Collaborator to Start Pivotal Study with Bimagrumab
      • Sep 26, 2013: Ultragenyx Announces Three Abstracts Accepted for Poster Presentation at 18th Annual World Muscle Society Congress
      • Aug 20, 2013: Novartis receives FDA breakthrough therapy designation for BYM338 (bimagrumab) for sporadic inclusion body myositis (sIBM)
      • Jul 03, 2013: Ultragenyx Announces a Positive Signal in Interim Data from Phase 2 Study of UX001 in Hereditary Inclusion Body Myopathy
      • Dec 15, 2011: New Zealand Pharma Obtains FDA Orphan Drug Designation For DEX-M74 To Treat Hereditary Inclusion Body Myopathy
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Inclusion Body Myositis (IBM), H2 2016
  • Number of Products under Development for Inclusion Body Myositis (IBM) - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Inclusion Body Myositis (IBM) - Pipeline by Acceleron Pharma, Inc., H2 2016
  • Inclusion Body Myositis (IBM) - Pipeline by Escala Therapeutics, Inc. , H2 2016
  • Inclusion Body Myositis (IBM) - Pipeline by Milo Biotechnology LLC, H2 2016
  • Inclusion Body Myositis (IBM) - Pipeline by Nobelpharma Co., Ltd., H2 2016
  • Inclusion Body Myositis (IBM) - Pipeline by Novartis AG, H2 2016
  • Inclusion Body Myositis (IBM) - Pipeline by Orphazyme ApS, H2 2016
  • Inclusion Body Myositis (IBM) - Pipeline by Ultragenyx Pharmaceutical Inc., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Inclusion Body Myositis (IBM) - Dormant Projects, H2 2016

List of Figures

  • Number of Products under Development for Inclusion Body Myositis (IBM), H2 2016
  • Number of Products under Development for Inclusion Body Myositis (IBM) - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top